Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections [clinicaltrials:NCT00427076]

Bio2RDF identifier

NCT00427076

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00427076

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00427076

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

250

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00427076 arm group 7fc56270e7a70fa81a5935b72eacbe29 [clinicaltrials_resource:NCT00427076/arm-group/7fc56270e7a70fa81a5935b72eacbe29]

NCT00427076 arm group 9d5ed678fe57bcca610140957afab571 [clinicaltrials_resource:NCT00427076/arm-group/9d5ed678fe57bcca610140957afab571]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:777b519f875bb71388f089265810b52d

brief summary [clinicaltrials_vocabulary:brief-summary]

Methicillin-resistant S ...... all-cause 30-day survival.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Cotrimoxazole Versus Vancomyci ...... aphylococcus Aureus Infections

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:4ce9e4145076950d45d5070d8ff606af]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:81b9fb60d84e2e9ee52d2d0e22bd3f8c]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:0acc8227ed4748d5fb1a6b4269d273a7]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:18e735d5e7c050c9093786f936f311cc]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:292ed45f5d91115e251abfb689a086c9]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:3517cb719dd8f9cbaa555fb4c0145e5a]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:3a661fc2fedd210a4b6082dd6e09db2d]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:460bead080b9d68861fe30d59a7945a4]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:5d1aca9e98d15d9667d9b6565ee0055f]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:6eefb1ece709398ced31be909c9f4693]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:ca2d08064c0689fecef362b1f55b93b7]

Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension 7 days [clinicaltrials_resource:d03cf10b3527520efb0fd05559e8c2c9]

completion date [clinicaltrials_vocabulary:completion-date]

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Staphylococcus aureus ( ...... documented infections.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00427076 [clinicaltrials_resource:338f800d153b08c4e452a815d5b8a057]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2007-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Cotrimoxazole [clinicaltrials_resource:25652ff8e00df099ced2b61b5ba26d4b]

Vancomycin [clinicaltrials_resource:62638e9fe9d1ded50cc1ead7e573da06]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Sulfamethoxazole [clinicaltrials_resource:01b2c823690f30d37206de1741ea48f3]

Vancomycin [clinicaltrials_resource:21a4dc4a1ee594e617ab97b6a4753dc8]

Methicillin [clinicaltrials_resource:945e61bd482aff2a901d331fef11bdda]

Trimethoprim-Sulfamethoxazole Combination [clinicaltrials_resource:a45af3c11c505503f3c043d1f35fcd47]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Health care association infections

http://www.w3.org/2001/XMLSchema#string

MRSA bacteremia or other micro ...... ed clinically by CDC criteria)

http://www.w3.org/2001/XMLSchema#string

Sepsis during hemodialysis, catheter-associated and catheter-related infections

http://www.w3.org/2001/XMLSchema#string

Surgical site infection in the presence of a foreign body

http://www.w3.org/2001/XMLSchema#string

Suspected neurosurgical meningitis

http://www.w3.org/2001/XMLSchema#string

Ventilator-associated pneumonia

http://www.w3.org/2001/XMLSchema#string

cotrimoxazole

http://www.w3.org/2001/XMLSchema#string

methicillin-resistant Staphylococcus aureus

http://www.w3.org/2001/XMLSchema#string

trimethoprim/ sulfamethoxazole

http://www.w3.org/2001/XMLSchema#string

vancomycin

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Rabin Medical Center [clinicaltrials_resource:9976ee48ade45b1420863fb0f7fee2a2]

location [clinicaltrials_vocabulary:location]

Rambam Health Care Campus [clinicaltrials_resource:4cab066a2f3b81e584f5cb2ffb531d96]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00427076

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Treatment With Cotrimoxazole v ...... s: Randomized Controlled Trial

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

Protocol V.3, dated 01.06.09

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Mical Paul, MD [clinicaltrials_resource:bf956c346a587667605d2c5a4419137a]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

Israel: Ethics Commission [clinicaltrials_resource:8b217ff2f8198a3813bb4c3ab385871d]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:9978a53c3f0b9ec07d9bcc29bd55f320]

source [clinicaltrials_vocabulary:source]

Rabin Medical Center [clinicaltrials_resource:9976ee48ade45b1420863fb0f7fee2a2]

start date [clinicaltrials_vocabulary:start-date]

2007-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00427076 study design [clinicaltrials_resource:236f43a92e3430dea895160c002bee51]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00427076

verification date [clinicaltrials_vocabulary:verification-date]

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00427076

http://www.w3.org/2001/XMLSchema#string

title

Cotrimoxazole Versus Vancomyci ...... aphylococcus Aureus Infections

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Cotrimoxazole Versus Vancomyci ...... s [clinicaltrials:NCT00427076]

@en